Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

Acquired or immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy with an annual incidence of three cases per 1 million adults [1]. In the pathogenesis, autoimm...